← Back to Patent Explorer
US4135975A Expired / Lapsed US ⏱️ 0.0 years remaining

Obtaining human cell lines that elaborate colony stimulating activity for marrow cells of man and other species and methods of preparing same

Assignee: Research Corp Technologies Inc
•
Filing: 1977-12-14
•
Granted: 1979-01-23
•
Expires: 1997-12-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Human cell lines have been obtained which elaborate colony stimulating activity (CSA) for marrow cells, i.e., which enable cells to be grown in vitro for use in bioassay methods in diagnostics and therapy. One cell line, GCT, was obtained from a lung metastasis of a fibrous histiocytoma and another, RC4 from a monocyte enriched fraction of normal blood. These cell lines provide a continuous source of large quantities of conditioned medium from purification of CSA and is more potent in stimulating human narrow growth in vitro than conditioned mediums heretofore available, i.e., human embryo kidney cell or human leukocyte feeder layers, having finite life spans in culture.

Inventors

  • 👤 Marshall A. Lichtman
  • 👤 James K. Brennan

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 13:24
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N5/0634; C12N5/0647; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/53; C12N2502/00; C12N2502/30

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 50 words
A method for stimulating in-vitro growth of bone marrow cells comprising conditioning a culture media with an active amount of a CSA agent defined as initially obtained from GCT or RC4 cells and their fragments; innoculating the conditioned media with the desired marrow cells; and incubating the resulting modified culture.
Claim 2
Independent Claim 50 words
A method for stimulating in-vitro growth of bone marrow cells comprising conditioning a culture media with an active amount of a CSA agent defined as initially obtained from GCT or RC4 cells and their fragments; innoculating the conditioned media with the desired marrow cells; and incubating the resulting modified culture.
Claim 3
Dependent Claim 39 words
The method of claim 1 wherein the conditioning CSA agent is initially obtained by culturing a population of human cells obtained from a malignant fibrous histiocytoma, said agent being defined as having a molecular weight of about 30,000-90,000 daltons.
Claim 4
Dependent Claim 36 words
The method of claim 1 wherein the CSA agent is initially obtained from a culture by-product of the plateletpheresis of normal human blood, said agent being defined as having a molecular weight of about 30,000-90,000 daltons.
Claim 5
Dependent Claim 30 words
The method as set forth in claim 2 wherein said culturing step is carried out with a medium containing fragments of said malignant fibrous histiocytoma, a nutrient, penicillin and streptomicin.
Claim 6
Dependent Claim 33 words
The method as set forth in claim 4 wherein said culturing step is carried out in a humidified atmosphere of air and CO 2 for a period of time of about four weeks.
Claim 7
Dependent Claim 51 words
The method as set forth in claim 3 including the step of enriching said human blood material to obtain a cell population which is rich in monocytes prior to said culturing step, and wherein said culturing step is carried out by incubation in a humidified atmosphere containing CO 2 in air.
Claim 8
Dependent Claim 37 words
A CSA conditioned medium for growing marrow cells in vitro consisting of a fluid in which a human cell line consisting of cells selected from the group consisting of GCT and RC4 is present and is cultured.
Claim 9
Dependent Claim 37 words
A CSA conditioned medium for growing marrow cells in vitro consisting of a fluid in which a human cell line consisting of cells selected from the group consisting of GCT and RC4 is present and is cultured.
Claim 10
Dependent Claim 27 words
The composition as set forth in claim 7 wherein the said medium contains CSA having an eluted molecular weight in the range of 30,000 to 90,000 daltons.

References Cited (Backward Citations)

US4021302A Cited
US4017361A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-01-22 1982-07-24 1983-01-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-01-22 1986-07-24 1987-01-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-01-22 1990-07-24 1991-01-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag